4526 POSTER Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment

Authors :: A. Le Cesne
J-M Ferrero
J. Krulik
Stéphane Oudard
Sylvie Negrier
G. Gravis
J.-Y. Blay
Olivier Rixe
N. Mahi
Source :: European Journal of Cancer Supplements. 5:306
Publication Year :: 2007
Publisher :: Elsevier BV, 2007.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
GiST
business.industry
Authorization
Sunitinib malate
medicine.disease
Safety profile
Imatinib mesylate
Renal cell carcinoma
Internal medicine
Cohort
medicine
Stromal tumor
business

Full Text Access

Tools